Blood tests may predict brain tumor treatment success
NCT ID NCT04817254
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 24 times
Summary
This study involved 47 adults with newly diagnosed glioblastoma or gliosarcoma who had already completed standard surgery, chemotherapy, and radiation. Researchers gave them a combination of immunotherapy drugs (ipilimumab and nivolumab) along with the chemotherapy drug temozolomide. The main goal was to see if changes in immune cells in the blood could predict how well the treatment worked and how long patients lived.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.